Drugs / Ad5-yCD/mutTKSR39rep-ADP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05686798 | Nov 2022 → Jan 2027 expected | brain cancer, glioblastoma | Henry Ford Health System | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-yCD/mutTKSR39rep-ADP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05686798 ↗ |